SG11202104104VA - Methods of producing two chain proteins in prokaryotic host cells - Google Patents

Methods of producing two chain proteins in prokaryotic host cells

Info

Publication number
SG11202104104VA
SG11202104104VA SG11202104104VA SG11202104104VA SG11202104104VA SG 11202104104V A SG11202104104V A SG 11202104104VA SG 11202104104V A SG11202104104V A SG 11202104104VA SG 11202104104V A SG11202104104V A SG 11202104104VA SG 11202104104V A SG11202104104V A SG 11202104104VA
Authority
SG
Singapore
Prior art keywords
producing
methods
host cells
prokaryotic host
chain proteins
Prior art date
Application number
SG11202104104VA
Inventor
Karthik Veeravalli
Rebekah Mckenna
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of SG11202104104VA publication Critical patent/SG11202104104VA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/90—Isomerases (5.)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y502/00—Cis-trans-isomerases (5.2)
    • C12Y502/01—Cis-trans-Isomerases (5.2.1)
    • C12Y502/01008—Peptidylprolyl isomerase (5.2.1.8), i.e. cyclophilin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
SG11202104104VA 2018-11-05 2019-11-04 Methods of producing two chain proteins in prokaryotic host cells SG11202104104VA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862755915P 2018-11-05 2018-11-05
PCT/US2019/059661 WO2020096959A1 (en) 2018-11-05 2019-11-04 Methods of producing two chain proteins in prokaryotic host cells

Publications (1)

Publication Number Publication Date
SG11202104104VA true SG11202104104VA (en) 2021-05-28

Family

ID=69165497

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202104104VA SG11202104104VA (en) 2018-11-05 2019-11-04 Methods of producing two chain proteins in prokaryotic host cells

Country Status (11)

Country Link
US (1) US20210261973A1 (en)
EP (1) EP3877407A1 (en)
JP (1) JP2022506156A (en)
KR (1) KR20210090645A (en)
CN (1) CN113260626A (en)
AU (1) AU2019375413A1 (en)
CA (1) CA3117051A1 (en)
IL (1) IL282800A (en)
SG (1) SG11202104104VA (en)
TW (1) TW202031899A (en)
WO (1) WO2020096959A1 (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230044394A (en) * 2020-06-09 2023-04-04 아이코사백스, 인크. Methods of making virus-like particles

Family Cites Families (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2413974A1 (en) 1978-01-06 1979-08-03 David Bernard DRYER FOR SCREEN-PRINTED SHEETS
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DD266710A3 (en) 1983-06-06 1989-04-12 Ve Forschungszentrum Biotechnologie Process for the biotechnical production of alkaline phosphatase
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
JP2919890B2 (en) 1988-11-11 1999-07-19 メディカル リサーチ カウンスル Single domain ligand, receptor consisting of the ligand, method for producing the same, and use of the ligand and the receptor
DE3920358A1 (en) 1989-06-22 1991-01-17 Behringwerke Ag BISPECIFIC AND OLIGO-SPECIFIC, MONO- AND OLIGOVALENT ANTI-BODY CONSTRUCTS, THEIR PRODUCTION AND USE
EP0739904A1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
DE69133566T2 (en) 1990-01-12 2007-12-06 Amgen Fremont Inc. Formation of xenogenic antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (en) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
CA2405246A1 (en) 1990-12-03 1992-06-11 Genentech, Inc. Enrichment method for variant proteins with alterred binding properties
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
CA2116774C (en) 1991-09-19 2003-11-11 Paul J. Carter Expression in e. coli antibody fragments having at least a cysteine present as a free thiol. use for the production of bifunctional f(ab') 2 antibodies
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
CA2129663C (en) 1992-02-06 2005-07-05 James S. Huston Biosynthetic binding protein for cancer marker
ATE149570T1 (en) 1992-08-17 1997-03-15 Genentech Inc BISPECIFIC IMMUNOADHESINS
AU691811B2 (en) 1993-06-16 1998-05-28 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
KR20050085971A (en) 1995-04-27 2005-08-29 아브게닉스, 인크. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP2314625B1 (en) 1996-12-03 2014-05-07 Amgen Fremont Inc. Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
DK1034298T3 (en) 1997-12-05 2012-01-30 Scripps Research Inst Humanization of murine antibody
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
JP2002510481A (en) 1998-04-02 2002-04-09 ジェネンテック・インコーポレーテッド Antibody variants and fragments thereof
JP2000083670A (en) * 1998-09-09 2000-03-28 Hsp Kenkyusho:Kk Dsba/dsbb/dsbc/dsbd-expression plasmid
ES2694002T3 (en) 1999-01-15 2018-12-17 Genentech, Inc. Polypeptide comprising an Fc region of variant human IgG1
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US20030180714A1 (en) 1999-12-15 2003-09-25 Genentech, Inc. Shotgun scanning
WO2002061090A2 (en) 2000-12-14 2002-08-08 Genentech, Inc. Prokaryotically produced antibodies and uses thereof
MXPA04001566A (en) * 2001-08-27 2004-05-17 Genentech Inc A system for antibody expression and assembly.
EP1513879B1 (en) 2002-06-03 2018-08-22 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
TWI335821B (en) 2002-12-16 2011-01-11 Genentech Inc Immunoglobulin variants and uses thereof
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
WO2004106381A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-cd3, anti-cd19 antibody constructs for the treatment of b-cell related disorders
PT1691833E (en) 2003-11-28 2010-06-08 Micromet Ag Compositions comprising polypeptides
CN100537771C (en) * 2003-12-04 2009-09-09 北京安波特基因工程技术有限公司 A kind of colibacillus periplasm solinocrine type expression vector
US7235641B2 (en) 2003-12-22 2007-06-26 Micromet Ag Bispecific antibodies
AU2005230848B9 (en) 2004-03-31 2011-06-02 Genentech, Inc. Humanized anti-TGF-beta antibodies
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
ES2403055T3 (en) 2004-04-13 2013-05-13 F. Hoffmann-La Roche Ag Anti-P-selectin antibodies
TWI380996B (en) 2004-09-17 2013-01-01 Hoffmann La Roche Anti-ox40l antibodies
AU2006301492B2 (en) 2005-10-11 2011-06-09 Amgen Research (Munich) Gmbh Compositions comprising cross-species-specific antibodies and uses thereof
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
US20070237764A1 (en) 2005-12-02 2007-10-11 Genentech, Inc. Binding polypeptides with restricted diversity sequences
CA2651567A1 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
RS53008B2 (en) 2007-04-03 2022-12-30 Amgen Res Munich Gmbh Cross-species-specific cd3-epsilon binding domain
EP2160469B1 (en) 2007-05-17 2018-02-28 Boehringer Ingelheim RCV GmbH & Co KG Method for producing a recombinant protein on a manufacturing scale
CN100592373C (en) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 Liquid crystal panel drive device and its drive method
GB201000588D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial host strain
GB201000591D0 (en) * 2010-01-14 2010-03-03 Ucb Pharma Sa Bacterial hoist strain
WO2011133886A2 (en) 2010-04-23 2011-10-27 Genentech, Inc. Production of heteromultimeric proteins
CA2841824C (en) * 2011-07-13 2021-07-13 Ucb Pharma, S.A. Bacterial host strain expressing recombinant dsbc
KR102106002B1 (en) 2011-10-11 2020-05-07 제넨테크, 인크. Improved assembly of bispecific antibodies
GB201208367D0 (en) * 2012-05-14 2012-06-27 Ucb Pharma Sa Biological product
WO2017106583A1 (en) * 2015-12-15 2017-06-22 Absci, Llc Cytoplasmic expression system
US20150353940A1 (en) 2013-08-05 2015-12-10 Absci, Llc Vectors for use in an inducible coexpression system
US10190145B2 (en) * 2013-04-19 2019-01-29 Sutro Biopharma, Inc. Expression of biologically active proteins in a bacterial cell-free synthesis system using bacterial cells transformed to exhibit elevated levels of chaperone expression
KR20170075793A (en) * 2014-11-05 2017-07-03 제넨테크, 인크. Methods of producing two chain proteins in bacteria
AU2015342964B2 (en) * 2014-11-05 2021-06-24 Genentech, Inc. Methods of producing two chain proteins in bacteria
CR20170240A (en) 2014-11-10 2018-04-03 Genentech Inc ANTI-INTERLEUCINA-33 ANTIBODIES AND THEIR USES

Also Published As

Publication number Publication date
US20210261973A1 (en) 2021-08-26
CN113260626A (en) 2021-08-13
AU2019375413A1 (en) 2021-05-27
EP3877407A1 (en) 2021-09-15
IL282800A (en) 2021-06-30
CA3117051A1 (en) 2020-05-14
JP2022506156A (en) 2022-01-17
KR20210090645A (en) 2021-07-20
WO2020096959A1 (en) 2020-05-14
TW202031899A (en) 2020-09-01

Similar Documents

Publication Publication Date Title
IL312989A (en) Il15/il15rα heterodimeric fc-fusion proteins
HK1254953A1 (en) Anti-vista antibodies and fragments
HK1248162A1 (en) Factor ix fusion proteins and methods of making and using same
EP3270937A4 (en) Anti-mica antigen binding fragments, fusion molecules, cells which express and methods of using
IL287373A (en) Methods of producing two chain proteins in bacteria
EP3279212A4 (en) Method for mass producing proteins in mesenchymal stem cells
EP3200761A4 (en) Promoting muscle building and repair and treating disorders related to collagen and pertinent proteins by using shilajit
EP3200582A4 (en) Compositions, kits, and methods to induce acquired cytoresistance using stress protein inducers
IL277009A (en) Process to reduce endotoxin in gelatin
HK1245297A1 (en) Methods of improving yield in recombinant protein production
HK1248272A1 (en) Host cell protein modification
EP3331563A4 (en) Anti-cd154 antibodies and methods of using them
EP3430035A4 (en) Production of proteins in labyrinthulomycetes
HK1255201A1 (en) Methods of producing two chain proteins in bacteria
SI3368579T1 (en) Hinge modified antibody fragments and methods of making
EP3357933A4 (en) Haemophilus influenzae fusion protein and construction method and use thereof
IL282800A (en) Methods of producing two chain proteins in prokaryotic host cells
PT3818078T (en) Methods of producing recombinant proteins
IL284803A (en) Methods of producing multimeric proteins in eukaryotic host cells
EP3438259A4 (en) Methanol-utilizing enzyme-derived novel protein and method for producing intended protein using same
EP3298035A4 (en) Methods and compositions related to antigen presenting proteins
EP3371605A4 (en) Protein quantitation in multicellular tissue specimens
EP3204767A4 (en) Utility of protein in the prediction of in vivo effects
EP3556856A4 (en) Novel host cell and production method for target protein using same
EP3495480A4 (en) Method for preparing peptide fragments, method for preparing protease to be used therein, and kit for preparing peptide fragments